Relevance of tumor microenvironment for progression, therapy and drug development

Anti-Cancer Drugs

Volumn 15, Issue 1, 2004, Pages 7-14

  Henning, Tobias ^a   Kraus, Michael ^b   Brischwein, Martin ^a   Otto, Angela M ^a   Wolf, Bernhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Hypoxia; Mathematical modeling; Microenvironment; Radiation therapy; Tumor therapy

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARIPORIDE; CYTOSTATIC AGENT; DOXORUBICIN; ETOPOSIDE; MITOMYCIN; PLASMID DNA; PORFIROMYCIN; TIRAPAZAMINE; VINCRISTINE;

ACIDIFICATION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL METABOLISM; CELL PH; CELL PROLIFERATION; COMPUTER MODEL; CYTOLOGY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXTRACELLULAR SPACE; GLYCOLYSIS; HEAD CANCER; HUMAN; HYPOXIA; IMMUNE DEFICIENCY; IONIZATION; METASTASIS; MICROENVIRONMENT; MICROVASCULATURE; NECK CANCER; NONHUMAN; PATHOPHYSIOLOGY; PERFUSION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TREATMENT PLANNING; TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

CELL HYPOXIA; CELL TRANSFORMATION, NEOPLASTIC; COMPUTER SIMULATION; DRUG DESIGN; HYDROGEN-ION CONCENTRATION; IMMUNE TOLERANCE; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 4344643796     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200401000-00002     Document Type: Review

References (83)

1. Shain KH, Landowski TH, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol 2000; 12:557-563.
2. Shah-Yukich AA, Nelson AC. Characterization of solid tumor microvasculature: a three-dimensional analysis using the polymer casting technique. Lab Invest 1988; 58:236-244.
3. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408-1416.
4. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995; 92:768-772.
5. Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995; 15:5363-5368.
6. Senger DR, Brown LF, Claffey KP, Dvorak HF. Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis 1994; 14:385-394.
7. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964-3968.
8. Young PR, Spevacek SM. Substratum acidification and proteinase activation by murine B16F10 melanoma cultures. Biochim Biophys Acta 1993; 1182:69-74.
9. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49:6449-6465.
10. Griffiths JR. Are cancer cells acidic? Br J Cancer 1991; 64:425-427.
11. Warburg O. The Metabolism of Tumours. London: Arnold Constable; 1930.
12. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000; 6:15-19.
13. Dellian M, Helmlinger G, Yuan F, Jain RK. Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients. Br J Cancer 1996; 74:1206-1215.
14. Martin GR, Jain RK. Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. Cancer Res 1994; 54:5670-5674.
15. Madshus IH. Regulation of intracellular pH in eukaryotic cells. Biochem J 1988; 250:1-8.
16. Frelin C, Vigne P, Ladoux A, Lazdunski M. The regulation of the intracellular pH in cells from vertebrates. Eur J Biochem 1988; 174:3-14.
17. Stubbs M, Veech RL, Griffiths JR. Tumor metabolism: the lessons of magnetic resonance spectroscopy. Adv Enz Reg 1995; 35:101-115.
18. Stubbs M, Rodrigues L, Howe FA, Wang J, Jeong KS, Veech RL, et al. Metabolic consequences of a reversed pH gradient in rat tumors. Cancer Res 1994; 54:4011-4016.
19. i homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 1993; 32:11042-11056.
20. Marino AA, Iliev IG, Schwalke MA, Gonzalez E, Marler KC, Flanagan CA. Association between cell membrane potential and breast cancer. Tumour Biol 1994; 15:82-89.
21. Binggeli R, Weinstein RC. Deficits in elevating membrane potential of rat fibrosarcoma cells after cell contact. Cancer Res 1985; 45:235-241.
22. Binggeli R, Weinstein RC. Membrane potentials and sodium channels: hypotheses for growth regulation and cancer formation based on changes in sodium channels and gap junctions. J Theor Biol 1986; 123:377-401.
23. Kato Y, Nakayama Y, Umeda M, Miyazaki K. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 1992; 267:11424-11430.
24. Ceccarini C, Eagle H. pH as a determinant of cellular growth and contact inhibition. Proc Natl Acad Sci USA 1971; 68:229-233.
25. Rebollo A, Gomez J, Martinez d A, Lastres P, Silva A, Perez-Sala D. Apoptosis induced by IL-2 withdrawal is associated with an intracellular acidification. Exp Cell Res 1995; 218:581-585.
26. Perez-Sala D, Collado-Escobar D, Mollinedo F. Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. J Biol Chem 1995; 270:6235-6242.
27. Park HJ, Makepeace CM, Lyons JC, Song CW. Effect of intracellular acidity and ionomycin on apoptosis in HL-60 cells. Eur J Cancer 1996; 32A:540-546.
28. Gottlieb RA, Nordberg J, Skowronski E, Babior BM. Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci USA 1996; 93:654-658.
29. 2+ associated with apoptosis. Methods Cell Biol 1995; 46:41-55.
30. Wei LY, Roepe PD. Low external pH and osmotic shock increase the expression of human MDR protein. Biochemistry 1994; 33:7229-7238.
31. Roepe PD. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein. Biochemistry 1992; 31:12555-12564.
32. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999; 14:169-177.
33. Schindler M, Grabski S, Hoff E, Simon SM. Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry 1996; 35:2811-2817.
34. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88-91.
35. Kinzler KW, Vogelstein B. Life (and death) in a malignant tumour. Nature 1996; 379:19-20.
36. Morita T, Nagaki T, Fukuda I, Okumura K. Clastogenicity of low pH to various cultured mammalian cells. Mutat Res 1992; 268:297-305.
37. Morita T. Low pH leads to sister-chromatid exchanges and chromosomal aberrations, and its clastogenicity is S-dependent. Mutat Res 1995; 334:301-308.
38. LeBoeuf RA, Kerckaert GA, Aardema MJ, Gibson DP. Multistage neoplastic transformation of Syrian hamster embryo cells cultured at pH 6.70. Cancer Res 1990; 50:3722-3729.
39. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-810.
40. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995; 14:3-15.
41. Hickman JA, Potten CS, Merritt AJ, Fisher TC. Apoptosis and cancer chemotherapy. Phil Trans R Soc Lond B Biol Sci 1994; 345:319-325.
42. Bedford JS, Mitchell JB. The effect of hypoxia on the growth and radiation response of mammalian cells in culture. Br J Radiol 1974; 47:687-696.
43. Durand RE. The influence of microenvironmental factors during cancer therapy. In vivo 1994; 8:691-702.
44. Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987; 5:313-341.
45. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235:1492-1495.
46. Gatenby RA. The potential role of transformation-induced metabolic changes in tumor-host interaction. Cancer Res 1995; 55:4151-4156.
47. Patel AA, Gawlinski ET, Lemieux SK, Gatenby RA. A cellular automaton model of early tumor growth and invasion. J Theor Biol 2001; 213:315-331.
48. Loeffler DA, Juneau PL, Masserant S. Influence of tumour physico-chemical conditions on interleukin-2-stimulated lymphocyte proliferation. Br J Cancer 1992; 66:619-622.
49. Persechini PM, Liu CC, Jiang S, Young JD. The lymphocyte pore-forming protein perforin is associated with granules by a pH-dependent mechanism. Immunol Lett 1989; 22:23-27.
50. Masson D, Peters PJ, Geuze HJ, Borst J, Tschopp J. Interaction of chondroitin sulfate with perforin and granzymes of cytolytic T-cells is dependent on pH. Biochemistry 1990; 29:11229-11235.
51. Severin T, Muller B, Giese G, Uhl B, Wolf B, Hauschildt S, et al. pH-dependent LAK cell cytotoxicity. Tumour Biol 1994; 15:304-310.
52. Loeffler DA, Juneau PL, Heppner GH. Natural killer-cell activity under conditions reflective of tumor micro-environment. Int J Cancer 1991; 48:895-899.
53. 2+ and pH. J Immunol 1991; 147:3638-3645.
54. Radosevic K, de Grooth BG, Greve J. Changes in intracellular calcium concentration and pH of target cells during the cytotoxic process: a quantitative study at the single cell level. Cytometry 1995; 20:281-289.
55. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996; 14:176-186.
56. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 1994; 54:6517-6525.
57. van der Stappen JW, Williams AC, Maciewicz RA, Paraskeva C. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 1996; 67:547-554.
58. Shimo T, Nakanishi T, Nishida T, Asano M, Sasaki A, Kanyama M, et al. Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis. Oncology 2001; 61:315-322.
59. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000; 76:589-605.
60. Kraus M, Wolf B. Structured Biological Modelling: A New Approach to Biophysical Cell Biology. Boca Raton, FL: CRC Press; 1995.
61. Kraus M, Wolf B. Emergence of self-organization in tumor cells: relevance for diagnosis and therapy. Tumour Biol 1993; 14:338-353.
62. Kraus M, Wolf B. Physicochemical microenvironment as key regulator for tumor microevolution, invasion and immune response: targets for endocytotechnological approaches in cancer treatment. Endocytobiol Cell Res 1998; 12:133-156.
63. Webb SD, Sherratt JA, Fish RG. Alterations in proteolytic activity at low pH and its association with invasion: a theoretical model. Clin Exp Metastasis 1999; 17:397-407.
64. Wolf B, Kraus M. [Importance of cell self-organization for tumor biology]. Naturwissenschaften 1993; 80:343-352.
65. Henning T, Brischwein M, Baumann W, Ehret R, Freund I, Kammerer R, et al. Approach to a multiparametric sensor-chip-based tumor chemosensitivity assay. Anticancer Drugs 2001; 12:21-32.
66. Wolf B, Brischwein M, Baumann W, Ehret R, Henning T, Lehmann M, et al. Microsensor-aided measurements of cellular signalling and metabolism on tumor cells. The cell monitoring system (cms(R)). Tumour Biol 1998; 19:374-383.
67. Mason RP. Transmembrane pH gradients in vivo: measurements using fluorinated vitamin B6 derivatives. Curr Med Chem 1999; 6:481-499.
68. Shaw AD, Li Z, Thomas Z, Stevens CW. Assessment of tissue oxygen tension: comparison of dynamic fluorescence quenching and polarographic electrode technique. Crit Care 2002; 6:76-80.
69. Ilangovan G, Li H, Zweier JL, Kuppusamy P. In vivo measurement of tumor redox environment using EPR spectroscopy. Mol Cell Biochem 2002; 234-235:393-398.
70. Gerweck LE. Tumor pH: implications for treatment and novel drug design. Semin Radiat Oncol 1998; 8:176-182.
71. Kozin SV, Shkarin P, Gerweck LE. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res 2001; 61:4740-4743.
72. Wong P, Kleemann HW, Tannock IF. Cytostatic potential of novel agents that inhibit the regulation of intracellular pH. Br J Cancer 2002; 87:238-245.
73. Haq R, Zanke B. Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Cancer Metastasis Rev 1998; 17:233-239.
74. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001; 18:243-259.
75. Rockwell S, Kennedy KA, Sartorelli AC. Mitomycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity. Int J Radiat Oncol Biol Phys 1982; 8:753-755.
76. Haffty BG, Son YH, Sasaki CT, Papac R, Fischer D, Rockwell S, et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 1993; 27:241-250.
77. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 2002; 62:5248-5253.
78. Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, et al. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther 2002; 9:946-954.
79. Fischer B, Muller B, Fisch P, Kreutz W. An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy. J Immunother 2000; 23:196-207.
80. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54:3352-3356.
81. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56:3540-3545.
82. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59:99-106.
83. Xiao F, Wei Y, Yang L, Zhao X, Tian L, Ding Z, et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 2002; 9:1207-1213.